Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

Rhea-AI Summary

Clearside Biomedical, Inc. (NASDAQ:CLSD) will report its third quarter 2022 financial results on November 9, 2022, before market open. Management will host a conference call at 8:30 a.m. ET to discuss results and provide corporate updates. The call can be accessed at (888) 506-0062 (domestic) or (973) 528-0011 (international) with conference code: 111701. Clearside specializes in innovative therapy delivery to the eye, utilizing its proprietary SCS Microinjector.

Positive

• Clearside's SCS Microinjector platform enables targeted delivery to the eye, potentially improving vision preservation.
• XIPERE, Clearside's first product, is commercially available in the U.S.

Negative

• None.

ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (888) 506-0062 (domestic) or (973) 528-0011 (international) and entering conference code: 111701. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical report its third quarter 2022 financial results?

Clearside Biomedical will report its third quarter 2022 financial results on November 9, 2022.

What time is the Clearside Biomedical conference call for financial results?

The conference call will be held at 8:30 a.m. Eastern Time on November 9, 2022.

How can I access the Clearside Biomedical conference call?

You can access the conference call by dialing (888) 506-0062 for domestic calls or (973) 528-0011 for international calls, using conference code 111701.

What is the significance of Clearside's SCS Microinjector?

The SCS Microinjector allows for non-surgical, targeted delivery of therapies to the back of the eye, potentially improving treatment outcomes.

What product has Clearside Biomedical commercially available in the U.S.?

Clearside's first product, XIPERE, a triamcinolone acetonide injectable suspension, is available for suprachoroidal use.